Quick Answer
ANI PHARMACEUTICALS INC reported Research And Development Expense of $51.66 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +15.9% in Research And Development Expense from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $11.50 million | Q4 2011: $6.70 million | Q1 2012: $5.18 million | Q2 2012: $209.9 thousand | Q3 2012: $148.7 thousand | Q4 2012: $2.51 million | Q1 2013: $296.0 thousand | Q2 2013: $437.0 thousand | Q3 2013: $454.0 thousand | Q1 2014: $376.0 thousand | Q2 2014: $851.0 thousand | Q3 2014: $883.0 thousand | Q1 2015: $403.0 thousand | Q2 2015: $995.0 thousand | Q3 2015: $815.0 thousand | Q1 2016: $966.0 thousand | Q2 2016: $764.0 thousand | Q3 2016: $1.04 million | Q1 2017: $1.62 million | Q2 2017: $2.17 million | Q3 2017: $2.63 million | Q1 2018: $2.10 million | Q2 2018: $5.14 million | Q3 2018: $4.67 million | Q1 2019: $4.37 million | Q2 2019: $5.77 million | Q3 2019: $4.98 million | Q1 2020: $6.34 million | Q2 2020: $3.04 million | Q3 2020: $2.94 million | Q1 2021: $2.97 million | Q2 2021: $2.81 million | Q3 2021: $2.46 million | Q1 2022: $5.27 million | Q2 2022: $4.17 million | Q3 2022: $7.66 million | Q1 2023: $5.92 million | Q2 2023: $7.37 million | Q3 2023: $11.12 million | Q1 2024: $10.51 million | Q2 2024: $7.30 million | Q3 2024: $10.13 million | Q1 2025: $10.56 million | Q2 2025: $16.54 million | Q3 2025: $12.30 million.
- Over the full 17 years of available data (2009 to 2025), ANI PHARMACEUTICALS INC's Research And Development Expense has grown by 277.6%.
- Historical annual values: Fiscal year 2025: $51.66 million | Fiscal year 2024: $44.58 million | Fiscal year 2023: $34.29 million | Fiscal year 2022: $22.32 million | Fiscal year 2021: $11.37 million | Fiscal year 2020: $16.00 million | Fiscal year 2019: $19.81 million | Fiscal year 2018: $15.39 million | Fiscal year 2017: $9.07 million | Fiscal year 2016: $2.91 million | Fiscal year 2015: $2.87 million | Fiscal year 2014: $2.68 million | Fiscal year 2013: $1.71 million | Fiscal year 2012: $1.16 million | Fiscal year 2011: $44.18 million | Fiscal year 2010: $39.71 million | Fiscal year 2009: $13.68 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: